Drug Trial Radar · NCT05066698
ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects
Last checked: Nov 19, 2026Latest source record: Oct 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
8
Actual
Start
Apr 27, 2022
Primary completion
Sep 7, 2022
Study completion Sep 7, 2022
Sponsor
- Lead sponsor
- Noveome Biotherapeutics, formerly StemnionIndustry
- Sponsor type
- Industry
- Collaborators
- IQVIA Biotech
- First posted
- Oct 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week open-label ST266 treatment period. All patients will be followed for 3-months post-treatment for monitoring of safety and maintenance of re-epithelialization.
Conditions
- Persistent Corneal Epithelial Defect
Interventions
ST266Biological
Topical ocular application: one drop four times a day for eight weeks
0.67% Sodium Chloride Ophthalmic SolutionOther
Topical ocular application: one drop four times a day for eight weeks
Open-label ST266Biological
Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical SuccessTime frame: 8 weeks
Locations
31 sites in 1 country. Site status is shown where the registry gives one.
Trinity Research Group
Dothan, Alabama
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Atlantis Eye Care
Huntington Beach, California
UCLA Stein Eye Institute
Los Angeles, California
Stanford
Palo Alto, California
UCLA Doheny Eye Center
Pasadena, California
California Eye Specialists Medical Group
Pasadena, California
Bowden Eye & Associates
Jacksonville, Florida
Shettle Eye Research
Largo, Florida
Millennium Clinical Research, Inc
Miami, Florida
MedEye Associates
Miami, Florida
Cincinnati Eye Institute
Edgewood, Kentucky
University of Maryland Eye Associates
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
Massachusetts Eye and Ear
Boston, Massachusetts
Mercy Clinic Eye Specialists- Ophthalmology
Springfield, Missouri
UNMC Truhlsen Eye Institute
Omaha, Nebraska
UNC Kittner Eye Center
Chapel Hill, North Carolina
Cincinnati Eye Institute
Cincinnati, Ohio
OSU Wexner Medical Center
Columbus, Ohio
Ophthalmic Partners, PC
Bala-Cynwyd, Pennsylvania
Vanderbilt Eye Institute
Nashville, Tennessee
Houston Eye Associates
Houston, Texas
Baylor College of Medicine
Houston, Texas
Blanton Eye Institute/Houston Methodist Eye Associates
Houston, Texas
Texas Eye Research Center
Hurst, Texas
R and R Eye Research, LLC
San Antonio, Texas
Piedmont Eye Center
Lynchburg, Virginia
WVU Eye Institute
Morgantown, West Virginia
The Eye Centers of Racine and Kenosha
Kenosha, Wisconsin
University of Wisconsin
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.